Update to Tucatinib/ONT380 phase 2 trial

[Debbie L.]

Me too, Pam (following with interest). There was a lot of HER2 at SABCS this year. Including, it seemed to me, more focus on the subgroups within (triple positive, and others that sort out genomically (spell check says that's not a word, but you know what I mean) to other than HER2-enriched in the HER2+ category).

But as always -- the more we learn, the more new questions arise that wait to be answered.

Debbie

PS: If anyone would like access to the "on demand" options to view the SABCS presentations, PM me and I'll give you the username/PW to access it. It usually all becomes available to the general public in January, if you're not in a hurry.